1
|
Yan ZY, Hu WQ, Zong QQ, Yu GH, Zhai CX, Wang LL, Wang YH, Zhang TY, Li Z, Teng Y, Cai J, Chen YF, Li M, Xu ZZ, Pan FM, Pan HF, Su H, Zou YF. Associations of RPEL1 and miR-1307 gene polymorphisms with disease susceptibility, glucocorticoid efficacy, anxiety, depression, and health-related quality of life in Chinese systemic lupus erythematosus patients. Lupus 2022; 31:1735-1743. [PMID: 36194484 DOI: 10.1177/09612033221131182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Our present study intended to examine the associations of RPEL1 and miR-1307 gene polymorphisms (rs4917385 and rs7911488) with susceptibility, glucocorticoids (GCs) efficacy, anxiety, depression, and health-related quality of life (HRQoL) in Chinese systemic lupus erythematosus (SLE) patients. METHODS Initially, 1000 participants (500 SLE cases and 500 controls) were recruited for the case-control study. Then, 429 cases who received GCs were followed through 12 weeks to explore GCs efficacy, depression, anxiety, and HRQoL. We selected the iMLDR technique for genotyping: RPEL1: rs4917385 (G/T) and miR-1307: rs7911488 (A/G). RESULTS The minor G allele of rs7911488 reduced the risk of SLE (p = .024). Four haplotypes consisting of rs4917385 and rs7911488 were associated with SLE susceptibility (p < .025). Both rs4917385 and rs7911488 were associated with anxiety symptoms and physical function (PF) in SLE patients (p < .025). The rs4917385 was associated with depression and its improvement. No statistical significance was found between RPEL1 and miR-1307 gene polymorphisms with GCs efficacy. Meanwhile, additive interaction analysis showed a significant association between RPEL1 and miR-1307 gene polymorphisms with tea consumption in anxiety. CONCLUSION RPEL1 and miR-1307 gene polymorphisms (rs4917385 and rs7911488) might be related to SLE susceptibility in Chinese population. Additionally, the two polymorphisms were possibly associated with depression, anxiety, and HRQoL in Chinese SLE population.
Collapse
Affiliation(s)
- Zi-Ye Yan
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China
| | - Wan-Qin Hu
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China
| | - Qi-Qun Zong
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China
| | - Guang-Hui Yu
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China
| | - Chun-Xia Zhai
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China
| | - Lin-Lin Wang
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China
| | - Yu-Hua Wang
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China
| | - Ting-Yu Zhang
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China
| | - Zhen Li
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China
| | - Ying Teng
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China
| | - Jing Cai
- Department of Rheumatology and Immunology, 36639The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Yang-Fan Chen
- Department of Rheumatology and Immunology, 36639The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Mu Li
- Department of Rheumatology and Immunology, 36639The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Zhou-Zhou Xu
- Department of Rheumatology and Immunology, 533251The Second Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Fa-Ming Pan
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China
| | - Hai-Feng Pan
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China
| | - Hong Su
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China
| | - Yan-Feng Zou
- Department of Epidemiology and Biostatistics, School of Public Health, 12485Anhui Medical University, Hefei, China.,12485The Key Laboratory of Anhui Medical Autoimmune Diseases (Anhui Medical University), Hefei, China.,Key Laboratory of Dermatology, (Anhui Medical University), Ministry of Education, Hefei, China
| |
Collapse
|
2
|
Ni P, Ma Y, Chung S. Mitochondrial dysfunction in psychiatric disorders. Schizophr Res 2022:S0920-9964(22)00333-4. [PMID: 36175250 DOI: 10.1016/j.schres.2022.08.027] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Revised: 08/25/2022] [Accepted: 08/30/2022] [Indexed: 11/30/2022]
Abstract
Psychiatric disorders are a heterogeneous group of mental disorders with abnormal mental or behavioral patterns, which severely distress or disable affected individuals and can have a grave socioeconomic burden. Growing evidence indicates that mitochondrial function plays an important role in developing psychiatric disorders. This review discusses the neuropsychiatric consequences of mitochondrial abnormalities in both animal models and patients. We also discuss recent studies associated with compromised mitochondrial function in various psychiatric disorders, such as schizophrenia (SCZ), major depressive disorder (MD), and bipolar disorders (BD). These studies employ various approaches including postmortem studies, imaging studies, genetic studies, and induced pluripotent stem cells (iPSCs) studies. We also summarize the evidence from animal models and clinical trials to support mitochondrial function as a potential therapeutic target to treat various psychiatric disorders. This review will contribute to furthering our understanding of the metabolic etiology of various psychiatric disorders, and help guide the development of optimal therapies.
Collapse
Affiliation(s)
- Peiyan Ni
- The Psychiatric Laboratory and Mental Health Center, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China.
| | - Yao Ma
- The Psychiatric Laboratory and Mental Health Center, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China
| | - Sangmi Chung
- Department of Cell Biology and Anatomy, New York Medical College, Valhalla, NY 10595, USA.
| |
Collapse
|
3
|
Domínguez-Zorita S, Romero-Carramiñana I, Cuezva JM, Esparza-Moltó PB. The ATPase Inhibitory Factor 1 is a Tissue-Specific Physiological Regulator of the Structure and Function of Mitochondrial ATP Synthase: A Closer Look Into Neuronal Function. Front Physiol 2022; 13:868820. [PMID: 35620611 PMCID: PMC9128019 DOI: 10.3389/fphys.2022.868820] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Accepted: 03/02/2022] [Indexed: 12/15/2022] Open
Abstract
The ATP synthase is an essential multifunctional enzyme complex of mitochondria that produces most of cellular ATP, shapes the structure of the inner membrane into cristae and regulates the signals that control cell fate or demise. The ATPase Inhibitory Factor 1 (IF1) functions in vivo as a physiological regulator of the ATP synthase and thereby controls mitochondrial structure and function, and the retrograde signaling pathways that reprogram nuclear gene expression. However, IF1 is not ubiquitously expressed in mammals, showing tissue-restricted expression in humans and mice and large expression differences between the two species in some tissues. Herein, we summarized key regulatory functions of IF1 for tissue homeostasis, with special emphasis on the deleterious effects that its genetic ablation in neurons has in learning. The development and characterization of tissue-specific mouse models with regulated expression of IF1 will be crucial to disentangle the contribution of the ATP synthase/IF1 axis in pathophysiology.
Collapse
Affiliation(s)
- Sonia Domínguez-Zorita
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, (CSIC-UAM), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) ISCIII, Instituto de Investigación Hospital 12 de Octubre, Universidad Autónoma de Madrid, Madrid, Spain
| | - Inés Romero-Carramiñana
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, (CSIC-UAM), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) ISCIII, Instituto de Investigación Hospital 12 de Octubre, Universidad Autónoma de Madrid, Madrid, Spain
| | - José M Cuezva
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, (CSIC-UAM), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) ISCIII, Instituto de Investigación Hospital 12 de Octubre, Universidad Autónoma de Madrid, Madrid, Spain
| | - Pau B Esparza-Moltó
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, (CSIC-UAM), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) ISCIII, Instituto de Investigación Hospital 12 de Octubre, Universidad Autónoma de Madrid, Madrid, Spain.,Salk Institute for Biological Studies, La Jolla, CA, United States
| |
Collapse
|